Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Change in Accured Expenses (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Change in Accured Expenses for 3 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 72.0% to $12.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.4 million through Dec 2025, up 80.61% year-over-year, with the annual reading at $12.4 million for FY2025, 80.61% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $12.6 million at Nuvation Bio, up from $8.6 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $12.6 million in Q4 2025, with the low at -$8.9 million in Q1 2025.
  • Average Change in Accured Expenses over 3 years is $1.6 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Change in Accured Expenses surged 455.38% in 2024, then crashed 692.12% in 2025.
  • Over 3 years, Change in Accured Expenses stood at -$2.1 million in 2023, then soared by 455.38% to $7.3 million in 2024, then soared by 72.0% to $12.6 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $12.6 million, $8.6 million, and $106000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.